Results 271 to 280 of about 3,927,360 (403)
A genetic linkage study of facioscapulohumeral (Landouzy-Dejerine) disease with 24 polymorphic DNA probes. [PDF]
Meena Upadhyaya+4 more
openalex +1 more source
Nanostructure and Corresponding Quenching Efficiency of Fluorescent DNA Probes. [PDF]
Guo W+5 more
europepmc +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Recombinant DNA Probes Used to Detect Genetic Disorders of the Liver [PDF]
Vincent J. Kidd, Savio L.C. Woo
openalex +1 more source
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho+11 more
wiley +1 more source
The use of DNA probes in preimplantation and prenatal diagnosis [PDF]
John D. West
openalex +1 more source
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau+9 more
wiley +1 more source
Chemical Methylation of RNA and DNA Viral Genomes as a Probe of In Situ Structure [PDF]
Minoru Yamakawa+2 more
openalex +1 more source
A quantitative assessment of the dynamic modification of lipid-DNA probes on live cell membranes. [PDF]
Bagheri Y+5 more
europepmc +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp+13 more
wiley +1 more source